1 Min Read
April 19 (Reuters) - Novo Nordisk A/S:
* XULTOPHY APPROVED IN CANADA FOR THE TREATMENT OF ADULTS WITH TYPE 2 DIABETES Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.